Xilio Therapeutics (NASDAQ:XLO) Posts Quarterly Earnings Results, Beats Estimates By $0.26 EPS

Xilio Therapeutics (NASDAQ:XLO) posted its quarterly earnings results on Wednesday. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.26, FiscalAI reports. Xilio Therapeutics had a negative return on equity of 151.42% and a negative net margin of 58.52%.The company had revenue of $18.69 million during the quarter, compared to analysts’ expectations of $12.72 million.

Xilio Therapeutics Stock Performance

XLO stock traded down $0.20 during mid-day trading on Wednesday, hitting $8.98. The company had a trading volume of 6,417 shares, compared to its average volume of 40,693. The firm has a market cap of $59.09 million, a PE ratio of -2.53 and a beta of -0.14. Xilio Therapeutics has a 12 month low of $6.47 and a 12 month high of $12.74. The stock’s fifty day moving average price is $8.84 and its two-hundred day moving average price is $8.36.

Analyst Ratings Changes

Several analysts recently weighed in on the stock. Wall Street Zen cut shares of Xilio Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, May 16th. Weiss Ratings downgraded shares of Xilio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, August 6th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock has an average rating of “Sell”.

Hedge Funds Weigh In On Xilio Therapeutics

Several institutional investors have recently bought and sold shares of the company. Jane Street Group LLC purchased a new stake in Xilio Therapeutics in the fourth quarter worth $27,000. Velan Capital Investment Management LP bought a new position in shares of Xilio Therapeutics during the 4th quarter worth $109,000. State Street Corp increased its holdings in Xilio Therapeutics by 13.7% in the 4th quarter. State Street Corp now owns 186,390 shares of the company’s stock worth $119,000 after acquiring an additional 22,500 shares during the last quarter. Squarepoint Ops LLC increased its holdings in Xilio Therapeutics by 39.6% in the 3rd quarter. Squarepoint Ops LLC now owns 328,794 shares of the company’s stock worth $277,000 after acquiring an additional 93,338 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in Xilio Therapeutics by 68.3% in the 4th quarter. Renaissance Technologies LLC now owns 344,416 shares of the company’s stock valued at $220,000 after acquiring an additional 139,716 shares during the period. Hedge funds and other institutional investors own 54.29% of the company’s stock.

About Xilio Therapeutics

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.